Navigation Links
Charles C. Harwood, Jr., Joins Cellectar, Inc.'s Board of Directors
Date:9/18/2008

MADISON, Wis., Sept. 18 /PRNewswire/ -- Cellectar, Inc., a privately-held radiopharmaceuticals company that designs and develops products to detect, treat and monitor human cancers, today announced the appointment of Charles C. Harwood, Jr., to the Company's Board of Directors.

Mr. Harwood, 55, is a Healthcare Industry Advisor for Avista Capital Partners, a NYC-based private equity firm. Prior to working with Avista, Mr. Harwood was President and Chief Executive Officer of privately-held Focus Diagnostics, Inc. from 2002 until the company's sale in 2006. With more than 20 years of experience in the healthcare industry, he has also served as Senior Vice President and Chief Financial Officer of Covance, Inc., one of world's largest drug development service companies.

"Charlie brings exceptional financial and transaction expertise to the Cellectar Board," commented William Clarke, MD, M.Sc, President and CEO of Cellectar. "His years of experience in the drug development industry will prove beneficial to the Company as we advance our radiopharmaceutical products toward clinical testing and commercialization."

Mr. Harwood also serves on the Board of Directors at BioReliance, Inc., a contract research organization specializing in biological safety testing and specialized toxicology, RadPharm, Inc., a privately-held contract research organization located in Princeton, NJ, and Itero Biopharmaceuticals, Inc., a development stage company located in the San Francisco Bay Area.

About Cellectar

Cellectar, Inc. is a radiopharmaceutical company that designs, develops and manufactures products to detect, treat and monitor a wide variety of human cancers. Cellectar's novel product candidates combine lipid-like molecules, phospholipid ethers (PLEs) analogs, with radioisotopes that can either image or destroy malignant cells. Cellectar's products' unique mechanism of action is based on their accumulation and selective retention in malignant tumors and not in normal cells. The Company's operations are based in Madison, WI. Cellectar has previously raised approximately $22.0 million from angel and venture capital investors; including Continuum Investment Partners and Venture Investors, LLC. For further information about Cellectar, visit the Company's website at http://www.cellectar.com.


'/>"/>
SOURCE Cellectar, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ocular Biopharmaceutical Company Charlesson Announces $1.6MM in New Funding and Upcoming Presentations at The Association for Research in Vision and Ophthalmology
2. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
3. Dr. Charles A. Sims of California Cryobanks Family Cord Blood Services Named to National Stem Cell Advisory Council
4. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
5. Informed Medical Communications Appoints Charles T. Saldarini to Board of Directors
6. Industry Pioneer Joins Profectus BioSciences to Support Innovation in Therapeutic and Preventative Vaccines
7. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
8. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
9. The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters
10. GM Exec Joins Bio-Reaction Industries Board of Directors
11. Nicholas J. Hart Joins Emisphere as Vice President, Strategy and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... Vincent R. Burton, MBBS, FRCA, ... licensed by the Bahamas’ National Stem Cell Ethics Committee (NSCEC). , Dr. Burton ... the West Indies. He went on to complete residency training in the United Kingdom ...
(Date:7/26/2017)... ... July 25, 2017 , ... Avery Products ... that enable short-run digital printing, is proud to announce that it has won ... Wizard online software available at avery.com/GHS . The products were recently honored ...
(Date:7/26/2017)... , ... July 25, 2017 , ... ... and manufacturing services that are necessary in the preparation and development of human ... biorepository facility operates under the US Food and Drug Administration’s (FDA) Current Good ...
(Date:7/26/2017)... , ... July 26, 2017 , ... ... company for the improvement of crop productivity and economics for the food, feed ... The scope of the agreement includes the research and development of microbiome-based seed ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... Report on Form 10-K on Thursday April 13, 2017 with the ... The ... section of the Company,s website at http://www.nxt-id.com  under "SEC Filings," ... 2016 Year Highlights: Acquisition of ...
(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
Breaking Biology News(10 mins):